$1.73
Today
as of Aug 5, 16:50 ET
Last 30 days
Recent Press Releases & News
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Innate Pharma Closes Enrollment in Phase 1 Advanced Solid Tumors Study
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Overview
52-week range
$1.17
$2.63
38% of range
Avg surprise (last 0)
—
Avg reaction (last 0)
—
Earnings trends
Implied volatility — last 90 days
No IV snapshots yet for IPHA.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.